FDA grants priority review for Actemra to treat giant cell arteritis – Healio

FDA grants priority review for Actemra to treat giant cell arteritis
Healio
The FDA has accepted Genentech’s supplemental biologics license application and has granted priority review for Actemra in the treatment of giant cell arteritis, according to a company press release.
FDA grants priority review for Roche’s Actemra to treat giant cell arteritisPulse Headlines
FDA Grants Priority Review for Actemra for Treatment of Giant Cell ArteritisManaged Care magazine
Tocilizumab Gets Priority Review for Treatment of Giant Cell ArteritisMonthly Prescribing Reference (registration)
Rare Disease Report –ETHealthworld.com –Tech Times –Business Wire (press release)
all 10 news articles »